论文部分内容阅读
报道１５例肝硬变患者静脉给予善得定（Ｓａｎｄｏｓｔａｔｉｎ）后，采用彩色多普勒超声扫查门脉系统血流动力学变化。结果：除门脉右支（ＲＰＶ）和门脉左支（ＬＰＶ）的血管内径（Ｄ）和血流量（ＢＦ）用药前、后差异无显著性意义（Ｐ＞０．０５）外，门脉其它血管用药前、后Ｄ、ＢＦ和血流速度（ＴＡＶ）（包括ＲＰＶ和ＬＰＶ的ＴＡＶ）差异均有显著性意义（Ｐ＜０．０５或＜０．０１），同样，门脉压力（Ｐｐｖ）差异亦有显著性意义（Ｐ＜０．０１），即代偿期肝硬化Ｐｐｖ下降１６．９２％，失代偿期肝硬变Ｐｐｖ下降１２．６％。上述结果提示，Ｓａｎｄｏｓｔａｔｉｎ通过收缩腹腔内脏血管，降低血流量，使门脉压力下降而达到止血目的。
Reported 15 patients with cirrhosis intravenously given Sandostatin (Sandostatin), the color Doppler ultrasound scanning portal system hemodynamic changes. Results: There was no significant difference between the two groups (P> 0.05) except for the difference of vascular diameter (D) and blood flow (BF) between the right portal vein (RPV) and left portal vein (LPV) There were significant differences in D, BF and TAV (including TAV of RPV and LPV) before and after other vasodilators (P <0.05 or <0.01). Similarly, portal pressure (Ppv ) Also had significant difference (P <0.01), that compensatory cirrhosis Ppv decreased 16.92%, decompensated cirrhosis Ppv decreased 12.6%. These results suggest that Sandostatin through the contraction of abdominal visceral blood vessels, reducing blood flow, portal pressure to achieve the purpose of bleeding.